

**Table 1: Comparison of clinical data between Group A and Group B.**

Variable		Group		Chi square or T test	P value
		A	B		
Age	Mean±SD	23.96±13.4	25.5±13.03	0.620	0.536(NS)
Age Group	Adult (>20 years)	42(42%)	17(42.5%)	0.003	0.957(NS)
	Young adults (12-20 years)	58(58%)	23(57.5%)		
Sex	Male	31(31%)	13(32.5%)	0.030	0.863(NS)
	Female	69(69%)	27(67.5%)		
Residence	Urban	46(46%)	20(50%)	0.183	0.668(NS)
	Rural	54(54%)	20(50%)		

NS : Non significant (P value >0.05) S: Significant (P value <0.05) HS: Highly significant (P value <0.001).

**Table 2: Comparison between 1st&4th generation Fluoroquinolones resistance in case group**

			Moxifloxacin		Total
			R	S	
Ciprofloxacin	R	Count	50	4	54
		%	50.0%	4.0%	54.0%
	S	Count	8	38	46
		%	8.0%	38.0%	46.0%
Total		Count	58	42	100
		%	58.0%	42.0%	100.0%

McNemar Chi square = 57.667, p value 0.388

NS : Non significant (P value >0.05) S: Significant (P value <0.05) HS: Highly significant (P value <0.001).

**Table 3: Comparison between outpatients & inpatients regarding drug sensitivity in case group**

Variable		Outpatients	Inpatients	Chi square	P value
Ampicillin	Resistant	60(90.9%)	34(100%)	3.288	0.076(NS)
	Sensitive	6(9.1%)	0		
Meropenem	Resistant	17(25.8%)	16(47.1%)	4.605	0.032(S)
	Sensitive	49(74.2%)	18(52.9%)		
Ciprofloxacin	Resistant	26(39.4%)	28(82.4%)	16.672	<0.001(HS)
	Sensitive	40(60.6%)	6(17.6%)		
Levofloxacin	Resistant	27(40.9%)	28(82.4%)	15.573	<0.001(HS)
	Sensitive	39(59.1%)	6(17.6%)		
Gatifloxacin	Resistant	29(43.9%)	29(85.3%)	15.754	<0.001(HS)
	Sensitive	37(56.1%)	5(14.7%)		
Moxifloxacin	Resistant	29(43.9%)	29(85.3%)	15.754	<0.001(HS)
	Sensitive	37(56.1%)	5(14.7%)		
Nitrofurantoin	Resistant	6(9.1%)	7(20.6%)	2.623	0.105(NS)
	Sensitive	60(90.9%)	27(79.4%)		

NS : Non significant (P value >0.05) S: Significant (P value <0.05) HS: Highly significant (P value <0.001).